ANA Mª
GONZÁLEZ-PINTO ARRILLAGA
Universidad de Extremadura
Badajoz, EspañaPublications in collaboration with researchers from Universidad de Extremadura (5)
2018
-
Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis
Schizophrenia Research, Vol. 193, pp. 188-196
-
Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis
Journal of Psychopharmacology, Vol. 32, Núm. 6, pp. 702-710
2017
-
Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients
European Neuropsychopharmacology, Vol. 27, Núm. 7, pp. 647-656
2016
-
A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
International Journal of Neuropsychopharmacology, Vol. 19, Núm. 4
-
Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: Role of dopamine, serotonin and glutamate candidate genes
Pharmacogenomics Journal, Vol. 16, Núm. 5, pp. 439-445